Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why

Shares of Arcturus Therapeutics Holdings Inc. (ARCT) have surged 73% in the past three months compared with the industry’s growth of 10.5%.Last month, the European Commission granted orphan medicinal product designation to the company’s product candidate ARCT-032 for the treatment of cystic fibrosis (CF). The designation is likely to support the development of ARCT-032, including certain protocol assistance, access to the centralized authorization procedure, exemption from fees and research funding, along w ...